ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ORGS Orgenesis Inc

0.5149
0.0289 (5.95%)
2024年6月1日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Orgenesis Inc ORGS NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.0289 5.95% 0.5149 13:00:10
始値 安値 高値 終値 前日終値
0.458 0.458 0.5298 0.5149 0.486
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/3119:14EDGAR2Form 8-K - Current report
2024/5/2422:16EDGAR2Form S-3/A - Registration statement under Securities Act of..
2024/5/2321:00EDGAR2Form 8-K - Current report
2024/5/2120:00GLOBEOrgenesis Provides Business Update for the First Quarter of..
2024/5/2105:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/1605:01EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
2024/5/0704:30EDGAR2Form ARS - Annual Report to Security Holders
2024/5/0704:28EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2024/5/0704:26EDGAR2Form DEF 14A - Other definitive proxy statements
2024/4/1606:07GLOBEOrgenesis Provides Year End Business Update
2024/4/1101:00GLOBEGermfree and Orgenesis Announce Asset Purchase and Strategic..
2024/3/1821:30GLOBEVered Caplan, CEO of Orgenesis, to Present at the..
2024/3/1321:30GLOBEOrgenesis Consortium Awarded €1.5M EUR Grant from the..
2024/3/0422:30GLOBEOrgenesis Inc. Announces $2.3 Million Private Placement
2024/2/2922:30GLOBEOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon..
2024/1/3123:20EDGAR2Form 8-K - Current report
2024/1/3123:15GLOBEOrgenesis Acquires Control of Octomera with the Goal of..
2024/1/2506:05EDGAR2Form 8-K - Current report
2024/1/2306:01EDGAR2Form 8-K - Current report
2024/1/0907:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0520:02EDGAR2Form 8-K - Current report
2023/11/1422:30GLOBEOrgenesis Ranked No. 171st Fastest-Growing Company in North..
2023/11/1406:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0921:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/11/0823:24EDGAR2Form 8-K - Current report
2023/11/0823:00GLOBEOrgenesis Inc. Announces Pricing of $1.1 Million Registered..
2023/11/0221:00GLOBEOrgenesis Announces Expanded Partnership Between Octomera..
2023/10/3110:30GLOBEOrgenesis Announces Withdrawal of Proposed Public Offering
2023/10/3105:07GLOBEOrgenesis Announces Proposed Underwritten Public Offering
2023/9/2121:00GLOBECGT Global and Octomera Enter Agreement to Expand Cell &..
2023/9/0620:00GLOBECell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard..
2023/9/0605:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/1120:00GLOBEOrgenesis Provides Business Update for Second Quarter of..
2023/8/1106:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1021:30GLOBEOrgenesis Schedules Second Quarter 2023 Business Update..
2023/7/1321:30GLOBEOrgenesis Appoints Finance Veteran Elliot Maltz as its Chief..
2023/7/1305:05EDGAR2Form 8-K - Current report
2023/7/1120:00GLOBEOrgenesis Announces Name Change of Morgenesis Business Unit..
2023/6/0720:00GLOBEOrgenesis and University of California, Davis Sign..